Myelodysplastic syndrome with isolated del(q) (q-syndrome)
Myelodysplastic syndrome (MDS), unclassifiable
Patients with a myelodysplastic/myeloproliferative neoplasm
Myelodysplastic or myeloproliferative syndrome other than MDS.
Myelodysplastic Syndrome (MDS)
Myelodysplastic syndrome
Any evidence of myelodysplastic syndrome or marrow chromosomal changes suggesting myelodysplasia (-, - etc)
Bone marrow examination revealing myelodysplastic syndrome or megakaryocyte underproduction for patients with a platelet count < ,/uL
No prior history of myelodysplastic syndrome or other myeloid malignancy
Prior treatment of myelodysplastic syndrome or myeloproliferative neoplasm with hypomethylating agent acceptable
Patients with a diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) that require therapy
Myelodysplastic/myeloproliferative disease\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Myelodysplastic syndrome and/or pre-leukemia at any stage
Myelodysplastic syndrome
Known history of myelodysplastic syndrome/leukemia at any time
Criteria  Myelodysplastic syndrome
Known presence of intermediate- or high-grade myelodysplastic syndrome.
Myelodysplastic syndrome (MDS) or myelofibrosis;
Myelodysplastic syndrome (MDS): primary or therapy related
Diagnosis of myelodysplastic syndrome.
History of myelodysplastic syndrome or organ transplantation
Patients with a history of myelodysplastic syndrome (MDS)
Myelodysplastic syndromes
History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least  year
For Cohort A: Has myelodysplastic syndrome
Presence of known intermediate- or high-grade myelodysplastic syndrome
Subject who has any histopathologic finding consistent with myelodysplastic syndrome on bone marrow studies.
Myelodysplastic syndrome
Known history of myelodysplastic syndrome (MDS).
Patients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastoma
Myelodysplastic syndrome
Patients who have a history of myelodysplastic syndrome
Diagnosis of Myelodysplastic Syndrome.
Prior treatment of myelodysplastic syndrome or myeloproliferative neoplasm acceptable
Myelodysplastic syndrome with fibrosis (MF )
A pathologically confirmed diagnosis of leukemia or myelodysplastic syndrome (MDS)
Myelodysplastic syndrome (MDS): primary or therapy related; or
Previously untreated for Myelodysplastic Syndrome (MDS)
Known presence of myelodysplastic syndrome
Known presence of myelodysplastic syndrome
Myelodysplastic Syndrome (MDS) at any stage.
Known presence of myelodysplastic syndrome
Myelodysplastic syndrome\r\n* =<  years of age and >= % blasts, not responsive to hypomethylating agents and/or conventional therapy
Diagnosis of myelodysplastic syndrome (MDS) or a hematologic malignancy.
Patients with low- and Int--risk myelodysplastic syndrome
Patients with myelodysplastic syndrome
Patients with myelodysplastic syndrome
Patients with myelodysplastic syndrome.
Myelodysplastic syndrome (MDS)
Known myelodysplastic syndrome
Known myelodysplastic syndrome.
Diagnosis of myelodysplastic syndrome (MDS).
Phase I: Hematologic malignancy diagnosis including any subset of myeloma, lymphoma, leukemia, or myelodysplastic syndrome
Phase II: Hematologic malignancy diagnosis including any subset of lymphoma, leukemia, or myelodysplastic syndrome
Known relapsed acute leukemia or myelodysplastic syndrome
Current Myelodysplastic syndrome only subjects
Subjects with a history of myelodysplastic syndrome
Diagnosed with hematological malignancy or marrow failure syndrome such as but not limited to: aplastic anemia, myelodysplastic syndrome or leukemia
Intermediate (Int)- or high risk myelodysplastic syndrome (MDS)
Subjects with treatment-related myelodysplastic syndrome.
A defined myelodysplastic syndrome(s) (MDS)
Myelodysplastic Syndrome
Current or prior history of myelodysplastic syndrome, leukemia or clinically significant (as per Investigator judgment) bone marrow failure.
